Status: Recruiting
Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies
The purpose of this open-label, single arm, multicenter extension study is to evaluate the long-term safety and tolerability of inclisiran in participants with HeFH or HoFH who have completed the ORION-16 (CKJX839C12301), ORION-13 (CKJX839C12302), ORION-20 (CKJX839C12303) or ORION-19 (CKJX839C12304) studies.
Participants needed: 195
Trial details
Phase: Phase 3Age: 12-100Biological sex: AllType: InterventionalSponsor: Novartis PharmaceuticalsUpdated: May 15, 2026Locations: 52
Eligibility criteria
Male and female participants with a diagnosis of HeFH or HoFH who completed the... [+3]